ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.
ONL Therapeutics has raised $65.0M in total funding. The most recent round was Series D. The last funding was announced in September 2024.
ONL Therapeutics's investors include Novartis, National Institutes of Health, Novartis Venture Fund, Johnson & Johnson Innovation JJDC, Visionary Venture Fund.
ONL Therapeutics is headquartered in Ann Arbor, United States.
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.
ONL Therapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ONL Therapeutics — Funding & Investors." VCBacked, September 13, 2024, https://www.vcbacked.co/company/onl-therapeutics. Accessed July 20, 2026.
VCBacked. (2024). ONL Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/onl-therapeutics
{{cite web |title=ONL Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/onl-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated